ADA 2026 Recap: 5 Key Presentations to Know

The American Diabetes Association (ADA) Scientific Sessions 2026, in New Orleans, Louisiana, gathered together some of the greatest minds in endocrinology to discuss the latest major clinical trials and technological advancements in diabetes and obesity care. From Eli Lilly’s triple receptor agonist retatrutide to the ultra-long-acting GLP-1 receptor agonist berobenatide made by Pfizer, this year’s meeting was dominated by major steps forward in incretin-based therapies.